Trials / Not Yet Recruiting
Not Yet RecruitingNCT06470672
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
A Phase 2 Study of SHR-A1921 Combined Adebrelimab in Endocrine Therapy-failed HR-positive, HER2-negative Advanced Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Our study is aimed to evaluate the efficacy and safety of novel ADC named SHR-A1921 combined with Adebrelimab in endocrine therapy-failed HR (Hormone Receptor)-positive, HER2-negative advanced breast cancer.
Conditions
- Advanced Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1921 | Anti-TROP-2 ADC |
| DRUG | Adebrelimab | PD-L1 inhibitor |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2026-03-01
- Completion
- 2026-07-01
- First posted
- 2024-06-24
- Last updated
- 2024-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06470672. Inclusion in this directory is not an endorsement.